RGEN: Repligen Corporation Stock

by  •  • Comments Off on RGEN: Repligen Corporation Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 9,113.87
Enterprise Value ($M) 8,851.51
Book Value ($M) 2,016.69
Book Value / Share 36.00
Price / Book 4.52
NCAV ($M) 317.61
NCAV / Share 5.67
Price / NCAV 28.69

Profitability (mra)
Return on Invested Capital (ROIC) -0.01
Return on Assets (ROA) -0.01
Return on Equity (ROE) -0.01

Liquidity (mrq)
Quick Ratio 8.76
Current Ratio 10.44

Balance Sheet (mrq) ($M)
Current Assets 1,131.57
Assets 2,830.64
Liabilities 813.96
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 634.44
Operating Income 44.96
Net Income -25.51
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
9 days ago 13G/A Price T Rowe Associates Inc /md/
02-13 13G/A Eddleman Roy T
11-12 13G/A BlackRock, Inc. 12.70 0.00
2024-02-13 13G/A Vanguard Group Inc 9.10 -2.44

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 119,522 625,313 19.11
2025-02-20 371,366 1,672,702 22.20
2025-02-19 209,490 984,650 21.28
2025-02-18 79,474 455,376 17.45

(click for more detail)

Similar Companies
RDUS – Radius Recycling, Inc. REGN – Regeneron Pharmaceuticals, Inc.
REPL – Replimune Group, Inc. RGNX – REGENXBIO Inc.
RIGL – Rigel Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io